AlShamlan Fatemah T, Alghazal Fatimah
Pediatric Ophthalmology and Strabismus Department, Dhahran Eye Specialist Hospital, Dhahran, Saudi Arabia.
Clin Ophthalmol. 2022 Aug 27;16:2843-2849. doi: 10.2147/OPTH.S382499. eCollection 2022.
To compare the effect of increment dose of botulinum toxin (BTX) injection in correlation to the angle of deviation to bilateral medial rectus recession (BMR) in infantile esotropia and partially accommodative esotropia (PAET).
This was a retrospective study that included pediatric patients ≤16 years old with infantile esotropia and PAET at Dhahran Eye Specialist Hospital (DESH) from 2014 till 2021 treated with increment dose of BTX or BMR. A successful outcome is defined as ocular alignment within 10 PD of deviation after 1-3 BTX injections or one surgery with a minimum follow-up of 6 months.
Of 177 patients, 101 patients received BTX treatment for either infantile esotropia (n = 37) or PAET (n = 64) and 76 patients underwent BMR for either infantile ET (n = 25) or PAET (n = 51). BTX showed a higher success rate than BMR {65.3% vs 55.3% (p = 0.174)}. In patients with infantile esotropia, the success rate was comparable between BTX group and BMR group {40.5% vs 52% (p = 0.440)}. However, the success rate was statistically significantly higher in BTX group in compare to BMR group {79.7% vs 56.9% (p = 0.014)}. Consecutive exotropia was 0% in BTX group and 9.2% in BMR group (p = 0.002).
The increment dose of BTX injection is comparable to surgery in patients with infantile esotropia but superior to the routine surgery in patients with PAET. BTX has the advantage of a shorter procedure duration, lower costs, less exposure to general anesthesia and being minimally invasive intervention.
比较肉毒杆菌毒素(BTX)递增剂量注射与双侧内直肌后徙术(BMR)对婴儿型内斜视和部分调节性内斜视(PAET)的斜视度的影响。
这是一项回顾性研究,纳入了2014年至2021年在达兰眼科专科医院(DESH)接受BTX递增剂量注射或BMR治疗的16岁及以下婴儿型内斜视和PAET儿科患者。成功结局定义为在1 - 3次BTX注射或一次手术后,斜视度在10棱镜度(PD)以内,且至少随访6个月。
177例患者中,101例患者因婴儿型内斜视(n = 37)或PAET(n = 64)接受了BTX治疗,76例患者因婴儿型内斜视(n = 25)或PAET(n = 51)接受了BMR。BTX的成功率高于BMR{65.3%对55.3%(p = 0.174)}。在婴儿型内斜视患者中,BTX组和BMR组的成功率相当{40.5%对52%(p = 0.440)}。然而,与BMR组相比,BTX组的成功率在统计学上显著更高{79.7%对56.9%(p = 0.014)}。BTX组的连续性外斜视发生率为0%,BMR组为9.2%(p = 0.002)。
BTX递增剂量注射在婴儿型内斜视患者中与手术效果相当,但在PAET患者中优于常规手术。BTX具有手术时间短、成本低、较少暴露于全身麻醉以及微创干预的优势。